Bisphosphonate-Induced Atypical Femoral Fractures: Pathogenesis Insights and the Role of Bioactive Collagen Peptides – A Case Report
Journal of Clinical Orthopaedics | Vol 9 | Issue 2 | July-December 2024 | page: 118-122 | Somasekhara Reddy Nallamilli, Mohan Krishna Althuri, Shruti Patwal, Manish R Garg
DOI: https://doi.org/10.13107/jcorth.2024.v09i02.690
Submitted Date: 10 Aug 2024, Review Date: 12 Sep 2024, Accepted Date: 15 Sep 2024 & Published Date: 10 Dec 2024
Author: Somasekhara Reddy Nallamilli [1], Mohan Krishna Althuri [1], Shruti Patwal [2], Manish R Garg [3]
[1] Department of Orthopedics, Apollo Hospitals, Hyderabad, Telangana, India,
[2] Department of Medical Affairs, Universal NutriScience, Mumbai, Maharashtra, India,
[3] Department of Medical Affairs, Universal NutriScience, Pharmacology, Mumbai, Maharashtra, India
Address of Correspondence
Dr. Manish R Garg,
Department of Medical Affairs, Universal NutriScience, Pharmacology, Mumbai, Maharashtra, India
E-mail: manish_rgarg@yahoo.co.in
Abstract
Introduction: Bisphosphonates (BPs) have emerged as the mainstay of osteoporosis treatment. However, over the past 10 years, atypical femoral fractures (AFFs) have been identified as a possible side effect of BP.
Case Report: A 73-year-old male with a history of prostate carcinoma and an isolated rib metastasis was being treated with zoledronic acid. Despite a successful intramedullary nail fixation and a healed fracture, 5 months later, he developed another fracture in the same femur in the subtrochanteric area. This case report delves into the intricate pathogenesis of BP-induced atypical femoral fractures (AFF) and explores the potential role of bioactive collagen peptides in their pathogenesis.
Conclusion: Significant challenges exist in diagnosing and managing BP-induced AFFs. Using anabolic agents and bioactive collagen peptides is a successful therapeutic intervention for these patients.
Keywords: Collagen peptides, nutraceuticals, osteoporosis, bisphosphonate-induced atypical fractures.
References
1. Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 2020;383:743-53.
2. Lindsay R, Cosman F. Osteoporosis. In: Jameson JL, Fauci AS, Kasper DL, Hauser ST, Longo DL, Loscazo J, editors. Harrison’s Principles of Internal Medicine. 20th ed., Vol. 2. New York: McGraw Hill; 2018. p. 2942-59.
3. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997;80:1652-60.
4. Ganesan K, Goyal A, Roane D. Bisphosphonate. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024.
5. Rudran B, Super J, Jandoo R, Babu V, Nathan S, Ibrahim E, et al. Current concepts in the management of bisphosphonate associated atypical femoral fractures. World J Orthop 2021;12:660-71.
6. Tile L, Cheung AM. Atypical femur fractures: Current understanding and approach to management. Ther Adv Musculoskelet Dis 2020;12:1759720X20916983.
7. Larsen MS, Schmal H. The enigma of atypical femoral fractures: A summary of current knowledge. EFORT Open Rev 2018;3:494-500.
8. Githens M, Garner MR, Firoozabadi R. Surgical management of atypical femur fractures associated with bisphosphonate therapy. J Am Acad Orthop Surg 2018;26:864-71.
9. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010;47:169-80.
10. Yoon RS, Beebe KS, Benevenia J. Prophylactic bilateral intramedullary femoral nails for bisphosphonate-associated signs of impending subtrochanteric hip fracture. Orthopedics 2010;33:267-70.
11. Pearce O, Edwards T, Al-Hourani K, Kelly M, Riddick A. Evaluation and management of atypical femoral fractures: An update of current knowledge. Eur J Orthop Surg Traumatol 2021;31:825-40.
12. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-44.
13. Adam M, Spacek P, Hulejova H, Galianova A, Blahos J. Postmenopausal osteoporosis. Treatment with calcitonin and a diet rich in collagen proteins. Cas Lek Cesk 1996;135:74-8.
14. Im GI, Jeong SH. Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab 2015;22:1-8.
15. König D, Oesser S, Scharla S, Zdzieblik D, Gollhofer A. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women-a randomized controlled study. Nutrients 2018;10:97.
16. Schneider JP, Hinshaw WB, Su C, Solow P. Atypical femur fractures: 81 individual personal histories. J Clin Endocrinol Metab 2012;97:4324-8.
17. Lin TL, Wang SJ, Fong YC, Hsu CJ, Hsu HC, Tsai CH. Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy. BMC Res Notes 2013;6:11.
18. Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: A comparison between treatment with and without teriparatide. J Bone Miner Metab 2014;33:553-9.
19. Gao J, Liu X, Wu X, Li X, Liu J, Li M. A brief review and clinical evidences of teriparatide therapy for atypical femoral fractures associated with long-term bisphosphonate treatment. Front Surg 2023;9:1063170.
20. Zdzieblik D, Oesser S, König D. Specific bioactive collagen peptides in osteopenia and osteoporosis: Long-term observation in postmenopausal women. J Bone Metab 2021;28:207-13.
| How to Cite this article: Nallamilli SR, Althuri MK, Patwal S, Garg MR. Bisphosphonate-Induced Atypical Femoral Fractures: Pathogenesis Insights and the Role of Bioactive Collagen Peptides – A Case Report. Journal of Clinical Orthopaedics July-December 2024;9(2):118-122. |
(Article Text HTML) (Download PDF)
